• Featured Product
  • KD/KO Validated

Biotin-conjugated GFAP Polyclonal antibody

GFAP Polyclonal Antibody for IHC

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

IHC

Conjugate

Biotin

Cat no : Biotin-16825

Synonyms

FLJ45472, GFAP



Tested Applications

Positive IHC detected inmouse brain tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

ApplicationDilution
Immunohistochemistry (IHC)IHC : 1:2500-1:10000
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

Biotin-16825 targets GFAP in IHC applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity human, mouse, rat
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen GFAP fusion protein Ag10423
Full Name glial fibrillary acidic protein
Calculated Molecular Weight 432 aa, 50 kDa
Observed Molecular Weight 45-50 kDa
GenBank Accession NumberBC013596
Gene Symbol GFAP
Gene ID (NCBI) 2670
RRIDAB_2918939
Conjugate Biotin
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3.
Storage ConditionsStore at -20°C. Avoid exposure to light. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Function
GFAP (Glial fibrillary acidic protein) is a type III intermediate filament (IF) protein specific to the central nervous system (CNS). GFAP is one of the main components of the intermediate filament network in astrocytes and has been proposed as playing a role in cell migration, cell motility, maintaining mechanical strength, and in mitosis.
Tissue specificity
GFAP is expressed in central nervous system cells, predominantly in astrocytes. GFAP is commonly used as an astrocyte marker. However, GFAP is also present in peripheral glia and in non-CNS cells, including fibroblasts, chondrocytes, lymphocytes, and liver stellate cells (PMID: 21219963).
Involvement in disease
  • Mutations in GFAP lead to Alexander disease (OMIM: 203450), an autosomal dominant CNS disorder. The mutations present in affected individuals are thought to be gain-of-function.
  • Upregulation of GFAP is a hallmark of reactive astrocytes, in which GFAP is present in hypertrophic cellular processes. Reactive astrogliosis is present in many neurological disorders, such as stroke, various neurodegenerative diseases (including Alzheimer's and Parkinson's disease), and neurotrauma.
Isoforms
Astrocytes express 10 different isoforms of GFAP that differ in the rod and tail domains (PMID: 25726916), which means that they differ in molecular size. Isoform expression varies during the development and across different subtypes of astrocytes. Not all isoforms are upregulated in reactive astrocytes.
Post-translational modifications
Intermediate filament proteins are regulated by phosphorylation. Six phosphorylation sites have been identified in GFAP protein, at least some of which are reported to control filament assembly (PMID: 21219963).
Cellular localization
GFAP localizes to intermediate filaments and stains well in astrocyte cellular processes.

Protocols

Product Specific Protocols
IHC protocol for Biotin GFAP antibody Biotin-16825Download protocol
Standard Protocols
Click here to view our Standard Protocols